Osteoporosis Management & Prevention

Bone is living tissue that is constantly being remodeled. Specialized cells called osteoblasts build new bone, while osteoclasts break down old bone. In a healthy, hormonally balanced body, these two processes are in equilibrium — bone is broken down and rebuilt at roughly equal rates, maintaining skeletal strength and density throughout adulthood.

Hormones are the master regulators of this remodeling process. Estrogen, in particular, plays a central role by restraining osteoclast activity. When estrogen levels are adequate, osteoclasts break down bone at a measured, controlled pace. When estrogen declines — as it does during perimenopause and especially after menopause — osteoclast activity accelerates dramatically. Bone is broken down faster than osteoblasts can rebuild it, and the result is a progressive loss of bone density that can lead to osteopenia (early bone loss) and eventually osteoporosis.

The numbers are striking. Women can lose up to 20 percent of their bone density in the five to seven years following menopause. By age 65, many women have lost enough bone mass to be at significant risk for fractures of the spine, hip, and wrist — fractures that can result in chronic pain, disability, loss of independence, and increased mortality.

Testosterone also plays an important role in bone health for both sexes. In men, testosterone is converted to estradiol (a form of estrogen) in bone tissue, where it supports osteoblast function and bone mineral density. Men with low testosterone are at increased risk for osteoporosis, although their bone loss tends to be more gradual than the rapid post-menopausal decline seen in women.

Other hormones that influence bone density include progesterone, which stimulates osteoblast activity and new bone formation; DHEA, which serves as a precursor to both estrogen and testosterone; growth hormone and IGF-1, which promote bone remodeling; and thyroid hormones, which regulate the overall rate of bone turnover. A comprehensive approach to osteoporosis must consider all of these hormonal factors.

The standard medical approach to osteoporosis typically involves bisphosphonate medications such as alendronate (Fosamax), risedronate (Actonel), or zoledronic acid (Reclast). These drugs work by inhibiting osteoclast activity, slowing the rate of bone breakdown. While they can improve bone density measurements on a DEXA scan, they come with significant limitations.

Bisphosphonates slow bone resorption but do not promote new bone formation. The bone that is preserved may become more brittle over time because the natural remodeling process — which replaces old, micro-damaged bone with fresh, structurally sound bone — is suppressed. Long-term bisphosphonate use has been associated with rare but serious complications including osteonecrosis of the jaw and atypical femur fractures.

Calcium and vitamin D supplementation, while important foundational measures, are insufficient on their own to prevent or reverse osteoporosis in the setting of hormone deficiency. Without the hormonal signals that direct calcium into bone tissue and regulate osteoblast activity, much of the supplemental calcium may be deposited in soft tissues (such as arterial walls) rather than in bone.

Bioidentical hormone replacement therapy offers a fundamentally different approach. By restoring the hormones that regulate bone remodeling at the cellular level, BHRT addresses the root cause of osteoporosis rather than simply slowing one aspect of bone metabolism. Research has consistently shown that estrogen therapy reduces fracture risk by 30 to 50 percent, and its benefits extend to cardiovascular health, cognitive function, and quality of life — benefits that bisphosphonates do not provide.

At The Riegel Center, Dr. Riegel designs personalized BHRT protocols that restore the full hormonal environment needed for healthy bone remodeling. This comprehensive approach goes far beyond what any single medication can achieve.

Bioidentical estrogen therapy restores the estrogen-mediated restraint on osteoclast activity, slowing the rate of bone resorption to normal levels. Unlike bisphosphonates, estrogen does not completely suppress remodeling — it restores the natural balance between bone breakdown and bone formation, allowing the skeleton to maintain its structural integrity and repair micro-damage.

Bioidentical progesterone complements estrogen by directly stimulating osteoblast activity and promoting new bone formation. This dual mechanism — reducing excessive breakdown while promoting new growth — is unique to hormone therapy and cannot be replicated by any single pharmaceutical agent.

Testosterone optimization supports bone health in both men and women. For men with low testosterone, testosterone replacement therapy has been shown to increase bone mineral density at the spine and hip. For women, small physiological doses of testosterone can enhance the bone-protective effects of estrogen and progesterone.

Dr. Riegel also evaluates and optimizes DHEA, thyroid function, and other hormonal factors that influence bone metabolism. His proprietary bioidentical formulas are individually compounded based on each patient's lab results and clinical needs, ensuring precise, personalized dosing that maximizes bone-protective benefits while minimizing risks.

Osteoporosis is often called a "silent disease" because bone loss occurs without symptoms until a fracture happens. By the time a fracture occurs, significant skeletal damage has already taken place. This is why proactive prevention is far more effective than reactive treatment.

Dr. Riegel recommends that women consider comprehensive hormonal evaluation and BHRT at the onset of perimenopause — ideally before significant bone loss has occurred. Starting hormone therapy during this critical window can prevent the rapid post-menopausal bone loss that leads to osteoporosis, rather than trying to recover density after it has already been lost.

For patients who already have osteopenia or osteoporosis, bioidentical hormone therapy can slow further bone loss, promote new bone formation, and reduce fracture risk. Combined with appropriate calcium and vitamin D supplementation, weight-bearing exercise, and lifestyle modifications, BHRT forms the cornerstone of a comprehensive bone health strategy.

Dr. Riegel monitors bone health through regular DEXA scans and blood markers of bone turnover, adjusting treatment protocols as needed to ensure ongoing protection. This proactive, data-driven approach gives patients the confidence that their skeletal health is being actively safeguarded.

Christopher J. Riegel's 30-plus years of clinical experience in hormone therapy give him unparalleled insight into the relationship between hormonal health and bone density. His proprietary bioidentical formulas are the product of decades of refinement and represent some of the most advanced compounded hormone therapies available in the United States.

Unlike conventional osteoporosis treatment, which typically addresses bone density in isolation, Dr. Riegel's approach treats the whole patient. By restoring hormonal balance, patients experience improvements not only in bone density but also in energy, mood, sleep, sexual health, and overall vitality — benefits that enhance every aspect of quality of life.

The Riegel Center also offers telehealth consultations for patients who cannot travel to Plano, TX, ensuring that expert hormonal osteoporosis management is accessible to individuals across the country.